论文部分内容阅读
目的使用双膦酸盐类药物对骨质疏松患者进行治疗,评估其临床疗效及安全性。方法随机抽取我院自2014年3月-2016年5月收治的骨质疏松患者共116例,随机分为治疗组、观察组各58例,治疗组给予双膦酸盐类药物进行治疗,观察组给予钙尔奇进行治疗,对患者的最终治疗效果进行观察统计。结果经治疗后,在疼痛缓解程度方面,治疗组有效率为39.66%;观察组有效率为13.79%。骨密度改善方面,两组患者均得到一定程度的改善,但是在Ward三角区、大转子、股骨颈及腰椎部位的骨密度改善方面,治疗组患者明显高于观察组患者。总有效率方面,治疗组患者为93.10%(54/58),观察组患者为72.41%(42/58)。不良反应发生率方面,治疗组为13.79%(8/58),观察组为34.48%(20/58)。结论使用双膦酸盐类药物对骨质疏松患者进行治疗,能够取得较好的治疗效果,且具有较高的安全性。
Objective To treat patients with osteoporosis with bisphosphonates and evaluate their clinical efficacy and safety. Methods One hundred and sixty-six patients with osteoporosis were randomly selected in our hospital from March 2014 to May 2016. They were randomly divided into treatment group (58 cases) and observation group (58 cases). Patients in the treatment group were treated with bisphosphonates and observed Group given calcic acid treatment, the final treatment of patients with the observation statistics. Results After treatment, the effective rate of the treatment group was 39.66% and that of the observation group was 13.79%. Bone mineral density improvement, both groups of patients have been some degree of improvement, but in the Ward triangle area, greater trochanter, femoral neck and lumbar spine bone mineral density improvement, the treatment group was significantly higher than the observation group. The total effective rate, the treatment group was 93.10% (54/58), the observation group was 72.41% (42/58). In the incidence of adverse reactions, the treatment group was 13.79% (8/58), the observation group was 34.48% (20/58). Conclusion The use of bisphosphonates for treatment of patients with osteoporosis, can achieve better therapeutic effect, and has high safety.